Literature DB >> 17095748

The chemokine receptor D6 has opposing effects on allergic inflammation and airway reactivity.

Gregory S Whitehead1, Tie Wang, Laura M DeGraff, Jeffrey W Card, Sergio A Lira, Gerard J Graham, Donald N Cook.   

Abstract

RATIONALE: The D6 chemokine receptor can bind and scavenge several chemokines, including the T-helper 2 (Th2)-associated chemokines CCL17 and CCL22. Although D6 is constitutively expressed in the lung, its pulmonary function is unknown.
OBJECTIVES: This study tested whether D6 regulates pulmonary chemokine levels, inflammation, or airway responsiveness during allergen-induced airway disease.
METHODS: D6-deficient and genetically matched C57BL/6 mice were sensitized and challenged with ovalbumin. ELISA and flow cytometry were used to measure levels of cytokines and leukocytes, respectively. Mechanical ventilation was used to measure airway reactivity.
RESULTS: The ability of D6 to diminish chemokine levels in the lung was chemokine concentration dependent. CCL17 and CCL22 were abundant in the airway, and their levels were attenuated by D6 when they were within a defined concentration range. By contrast, airway concentrations of CCL3, CCL5, and CCL11 were low and unaffected by D6. Allergen-challenged D6-deficient mice had more dendritic cells, T cells, and eosinophils in the lung parenchyma and more eosinophils in the airway than similarly challenged C57BL/6 mice. By contrast, D6-deficient mice had reduced airway responses to methacholine compared with C57BL/6 mice. Thus, D6 has opposing effects on inflammation and airway reactivity.
CONCLUSIONS: The ability of D6 to scavenge chemokines in the lung is dependent on chemokine concentration. The absence of D6 increases inflammation, but reduces airway reactivity. These findings suggest that inhibiting D6 function might be a novel means to attenuate airway responses in individuals with allergic asthma.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17095748      PMCID: PMC1899265          DOI: 10.1164/rccm.200606-839OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  34 in total

1.  Chemokine scavenging by D6: a movable feast?

Authors:  Gerard J Graham; Clive S McKimmie
Journal:  Trends Immunol       Date:  2006-06-30       Impact factor: 16.687

2.  CD4(+) T helper cells engineered to produce latent TGF-beta1 reverse allergen-induced airway hyperreactivity and inflammation.

Authors:  G Hansen; J J McIntire; V P Yeung; G Berry; G J Thorbecke; L Chen; R H DeKruyff; D T Umetsu
Journal:  J Clin Invest       Date:  2000-01       Impact factor: 14.808

3.  Allergic lung responses are increased in prostaglandin H synthase-deficient mice.

Authors:  S H Gavett; S L Madison; P C Chulada; P E Scarborough; W Qu; J E Boyle; H F Tiano; C A Lee; R Langenbach; V L Roggli; D C Zeldin
Journal:  J Clin Invest       Date:  1999-09       Impact factor: 14.808

4.  LD78beta, a non-allelic variant of human MIP-1alpha (LD78alpha), has enhanced receptor interactions and potent HIV suppressive activity.

Authors:  R J Nibbs; J Yang; N R Landau; J H Mao; G J Graham
Journal:  J Biol Chem       Date:  1999-06-18       Impact factor: 5.157

5.  Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophage-derived chemokine.

Authors:  T Imai; M Nagira; S Takagi; M Kakizaki; M Nishimura; J Wang; P W Gray; K Matsushima; O Yoshie
Journal:  Int Immunol       Date:  1999-01       Impact factor: 4.823

6.  Reduced expression of transforming growth factor beta 1 exacerbates pathology in an experimental asthma model.

Authors:  Wiebke Scherf; Stefan Burdach; Gesine Hansen
Journal:  Eur J Immunol       Date:  2005-01       Impact factor: 5.532

7.  Molecular cloning of a novel human CC chemokine (Eotaxin-3) that is a functional ligand of CC chemokine receptor 3.

Authors:  M Kitaura; N Suzuki; T Imai; S Takagi; R Suzuki; T Nakajima; K Hirai; H Nomiyama; O Yoshie
Journal:  J Biol Chem       Date:  1999-09-24       Impact factor: 5.157

8.  Interleukin-13: central mediator of allergic asthma.

Authors:  M Wills-Karp; J Luyimbazi; X Xu; B Schofield; T Y Neben; C L Karp; D D Donaldson
Journal:  Science       Date:  1998-12-18       Impact factor: 47.728

9.  Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes.

Authors:  F Sallusto; D Lenig; C R Mackay; A Lanzavecchia
Journal:  J Exp Med       Date:  1998-03-16       Impact factor: 14.307

10.  Human macrophage-derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells.

Authors:  R Godiska; D Chantry; C J Raport; S Sozzani; P Allavena; D Leviten; A Mantovani; P W Gray
Journal:  J Exp Med       Date:  1997-05-05       Impact factor: 14.307

View more
  29 in total

1.  Allergic sensitization through the airway primes Th17-dependent neutrophilia and airway hyperresponsiveness.

Authors:  Rhonda H Wilson; Gregory S Whitehead; Hideki Nakano; Meghan E Free; Jay K Kolls; Donald N Cook
Journal:  Am J Respir Crit Care Med       Date:  2009-08-06       Impact factor: 21.405

2.  Modulation of allergic airway inflammation by the oral pathogen Porphyromonas gingivalis.

Authors:  Jeffrey W Card; Michelle A Carey; James W Voltz; J Alyce Bradbury; Catherine D Ferguson; Eric A Cohen; Samuel Schwartz; Gordon P Flake; Daniel L Morgan; Samuel J Arbes; David A Barrow; Silvana P Barros; Steven Offenbacher; Darryl C Zeldin
Journal:  Infect Immun       Date:  2010-03-22       Impact factor: 3.441

3.  Cell-autonomous regulation of neutrophil migration by the D6 chemokine decoy receptor.

Authors:  Antal Rot; Clive McKimmie; Claire L Burt; Kenneth J Pallas; Thomas Jamieson; Monika Pruenster; Richard Horuk; Robert J B Nibbs; Gerard J Graham
Journal:  J Immunol       Date:  2013-05-13       Impact factor: 5.422

4.  A novel mechanism for CCR4 in the regulation of macrophage activation in bleomycin-induced pulmonary fibrosis.

Authors:  Glenda Trujillo; Erica C O'Connor; Steven L Kunkel; Cory M Hogaboam
Journal:  Am J Pathol       Date:  2008-04-10       Impact factor: 4.307

5.  The atypical chemokine receptor D6 contributes to the development of experimental colitis.

Authors:  Yvonne Bordon; Chris A H Hansell; David P Sester; Mairi Clarke; Allan McI Mowat; Robert J B Nibbs
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

Review 6.  Innate immune control of pulmonary dendritic cell trafficking.

Authors:  Donald N Cook; Kim Bottomly
Journal:  Proc Am Thorac Soc       Date:  2007-07

7.  The atypical chemokine receptor D6 suppresses the development of chemically induced skin tumors.

Authors:  Robert J B Nibbs; Derek S Gilchrist; Vicky King; Antonio Ferra; Steve Forrow; Keith D Hunter; Gerard J Graham
Journal:  J Clin Invest       Date:  2007-07       Impact factor: 14.808

Review 8.  DARC and D6: silent partners in chemokine regulation?

Authors:  Chris A H Hansell; Catherine E Hurson; Robert J B Nibbs
Journal:  Immunol Cell Biol       Date:  2010-12-14       Impact factor: 5.126

9.  Elevated expression of the chemokine-scavenging receptor D6 is associated with impaired lesion development in psoriasis.

Authors:  Mark D Singh; Vicky King; Helen Baldwin; David Burden; Anne Thorrat; Susan Holmes; Iain B McInnes; Ruairidh Nicoll; Kave Shams; Kenneth Pallas; Thomas Jamieson; Kit Ming Lee; Jose M Carballido; Antal Rot; Gerard J Graham
Journal:  Am J Pathol       Date:  2012-08-04       Impact factor: 4.307

Review 10.  International Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.

Authors:  Francoise Bachelerie; Adit Ben-Baruch; Amanda M Burkhardt; Christophe Combadiere; Joshua M Farber; Gerard J Graham; Richard Horuk; Alexander Hovard Sparre-Ulrich; Massimo Locati; Andrew D Luster; Alberto Mantovani; Kouji Matsushima; Philip M Murphy; Robert Nibbs; Hisayuki Nomiyama; Christine A Power; Amanda E I Proudfoot; Mette M Rosenkilde; Antal Rot; Silvano Sozzani; Marcus Thelen; Osamu Yoshie; Albert Zlotnik
Journal:  Pharmacol Rev       Date:  2013-11-11       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.